CA2737025C - Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof - Google Patents

Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof Download PDF

Info

Publication number
CA2737025C
CA2737025C CA2737025A CA2737025A CA2737025C CA 2737025 C CA2737025 C CA 2737025C CA 2737025 A CA2737025 A CA 2737025A CA 2737025 A CA2737025 A CA 2737025A CA 2737025 C CA2737025 C CA 2737025C
Authority
CA
Canada
Prior art keywords
composition
oil
cholesterol
acid
finasteride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2737025A
Other languages
English (en)
French (fr)
Other versions
CA2737025A1 (en
Inventor
Shoukath M. Ali
Ateeq Ahmad
Moghis U. Ahmad
Saifuddin Sheikh
Imran Ahmad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jina Pharmaceuticals Inc
Original Assignee
Jina Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42060413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2737025(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jina Pharmaceuticals Inc filed Critical Jina Pharmaceuticals Inc
Publication of CA2737025A1 publication Critical patent/CA2737025A1/en
Application granted granted Critical
Publication of CA2737025C publication Critical patent/CA2737025C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2737025A 2008-09-27 2009-09-25 Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof Active CA2737025C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10071408P 2008-09-27 2008-09-27
US61/100,714 2008-09-27
PCT/US2009/058463 WO2010036947A2 (en) 2008-09-27 2009-09-25 Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof

Publications (2)

Publication Number Publication Date
CA2737025A1 CA2737025A1 (en) 2010-04-01
CA2737025C true CA2737025C (en) 2012-09-04

Family

ID=42060413

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2737025A Active CA2737025C (en) 2008-09-27 2009-09-25 Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof

Country Status (15)

Country Link
US (1) US9750812B2 (enExample)
EP (1) EP2344198B1 (enExample)
JP (3) JP2012504135A (enExample)
CA (1) CA2737025C (enExample)
CY (1) CY1123579T1 (enExample)
DK (1) DK2344198T3 (enExample)
ES (1) ES2834006T3 (enExample)
HR (1) HRP20201860T1 (enExample)
HU (1) HUE052571T2 (enExample)
LT (1) LT2344198T (enExample)
MX (1) MX2011003207A (enExample)
PL (1) PL2344198T3 (enExample)
PT (1) PT2344198T (enExample)
SI (1) SI2344198T1 (enExample)
WO (1) WO2010036947A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9861154B2 (en) 2008-07-18 2018-01-09 Biomod Collection Inc. Articles of manufacture releasing an active ingredient
US9588118B2 (en) 2010-09-24 2017-03-07 Follea International Devices for performing colorimetric assay with plucked human hair
US8691518B2 (en) * 2010-09-24 2014-04-08 Global Life Science Partners Limited Systems and methods for predicting response to minoxidil for the treatment of androgenetic alopecia
US10633688B2 (en) 2010-09-24 2020-04-28 Follea International Systems and methods for predicting response to minoxidil for the treatment of androgenetic alopecia
ITMI20102165A1 (it) * 2010-11-23 2012-05-24 Medichem Srl Composizione per il lavaggio dei capelli e del cuoio capelluto
CN106890100A (zh) * 2011-04-25 2017-06-27 朴俊炯 用于预防脱发和促进毛发生长的局部施用的组合物
WO2013123466A1 (en) * 2012-02-16 2013-08-22 Brightside Innovations, Inc. Dietary and nutritional compositions and methods of use
WO2013160896A1 (en) * 2012-04-25 2013-10-31 Hadasit Medical Research Services And Development Ltd. Pomegranate oil for preventing and treating neurodegenerative diseases
BR102012022034B1 (pt) 2012-08-31 2020-02-18 Biolab Sanus Farmacêutica Ltda. Nanopartícula polimérica de finasterida, suspensão aquosa contendo a mesma, composição para tratamento de alopecia, processo de preparação de dita composição, e seu uso
BR102012022036B1 (pt) * 2012-08-31 2019-10-01 Biolab Sanus Farmacêutica Ltda. Nanopartícula polimérica de finasterida e minoxidil, processo de sua preparação, suspensão aquosa contendo a mesma, composição farmacêutica, e seu uso
WO2014078929A1 (pt) * 2012-11-26 2014-05-30 Universidade Federal De Minas Gerais - Ufmg Formulações tópicas para a prevenção e tratamento da alopecia e para inibição do crescimento de pêlos
RU2715103C2 (ru) * 2013-05-03 2020-02-27 Липидор Аб Местная композиция и носитель для введения фармацевтически или косметически активных ингредиентов
WO2015023926A1 (en) 2013-08-15 2015-02-19 Mary Kay Inc. Topical skin compositions for treating wrinkles
US20150147382A1 (en) * 2013-09-23 2015-05-28 Exir Nano Sina Company Topical liposomal compositions for delivering hydrophobic drugs and methods preparing same
US11660344B2 (en) 2013-11-17 2023-05-30 Medrx Co., Ltd. Transdermal colloidal solution agent
CN105722502A (zh) * 2013-11-17 2016-06-29 株式会社梅德瑞科思 经皮吸收胶体型液体制剂
AU2015337807B2 (en) * 2014-10-29 2017-05-04 Samson Clinical Pty Ltd Detection and treatment of excessive hair shedding
EP3038053B1 (en) 2014-12-22 2019-11-06 Reactive Reality GmbH Method and system for generating garment model data
US11298318B2 (en) * 2015-04-13 2022-04-12 Fountain Technologies International, Llc One-step method for production of ultra-small lipid structures
JPWO2016186157A1 (ja) * 2015-05-19 2018-03-08 株式会社 メドレックス 経皮吸収型液剤
JP7186093B2 (ja) * 2016-04-19 2022-12-08 ナンヤン テクノロジカル ユニヴァーシティー 前眼部疾患の治療のためのタクロリムスの持続送達用ナノリポソーム
AU2017350499B2 (en) 2016-10-28 2023-08-10 Les Laboratoires Servier Liposomal formulation for use in the treatment of cancer
BR112019025104A2 (pt) 2017-05-30 2020-06-23 Glaxosmithkline Biologicals S.A. Método de fabricar um sistema de entrega não viral, sistema de entrega não viral, e, composição
GB2600653B (en) * 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel methods
JP7191927B2 (ja) * 2017-07-12 2022-12-19 サムソン クリニカル プロプライエタリー リミテッド 育毛促進及び脱毛または過剰な毛髪脱落の治療
CA3080205A1 (en) * 2017-10-27 2019-05-02 TopiRX Therapeutics Inc. Topical formulations for treating dermatological disorders including male pattern baldness
MX390288B (es) * 2018-02-06 2025-03-20 Centro Int De Cosmiatria S A P I De C V Formulación y método para el tratamiento de la alopecia androgénica.
AU2019282155A1 (en) 2018-06-04 2021-01-07 Lars BRICHTA Topical compositions for stimulating hair growth
US11311529B2 (en) 2018-11-08 2022-04-26 Varsona Therapeutics, Inc. Topical formulations of 5-α-reductase inhibitors and uses thereof
EP3886901A1 (en) 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
EP4021407A1 (en) 2019-08-30 2022-07-06 GlaxoSmithKline Biologicals S.A. Jet mixing lipid nanoparticle manufacturing process
CA3182478A1 (en) * 2020-05-12 2021-11-18 Chemistry Rx Compositions for treating hair loss
US11311556B2 (en) 2020-05-13 2022-04-26 Varsona Therapeutics, Inc. Topical dutasteride emulsions for treating endocrine therapy-induced alopecia
US11850300B2 (en) 2022-03-17 2023-12-26 Rally Guide Topical lotion composition, methods of use, and methods of preparation
CN121487722A (zh) * 2023-04-14 2026-02-06 北京剂泰生命科技有限公司 靶向脾的脂质纳米颗粒
CN121752252A (zh) * 2023-08-16 2026-03-27 吉纳制药公司 含有mTOR抑制剂和脂质的组合物

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0753661B2 (ja) * 1984-03-08 1995-06-07 フアレス フアーマスーチカル リサーチ エヌブイ プロ―リポソーム組成物及びリポソームの水性分散物を作る方法
US4663167A (en) * 1984-04-16 1987-05-05 The Board Of Regents Of The University Of Texas System Composition and method for treatment of disseminated fungal infections in mammals
US4761288A (en) * 1984-09-24 1988-08-02 Mezei Associates Limited Multiphase liposomal drug delivery system
DE3576117D1 (de) * 1984-09-24 1990-04-05 Michael Mezei Mehrphasige pharmazeutische zusammensetzung.
US4897269A (en) * 1984-09-24 1990-01-30 Mezei Associates Limited Administration of drugs with multiphase liposomal delivery system
US6406713B1 (en) * 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
US5616334A (en) * 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
US4828837A (en) * 1987-03-30 1989-05-09 Liposome Technology, Inc. Non-crystalline minoxidil composition, its production and application
US5030442A (en) * 1987-03-30 1991-07-09 Liposome Technology, Inc. Non-crystalline minoxidil composition
DE3888994T2 (de) 1987-04-03 1994-11-03 Merck & Co Inc Behandlung von androgener Alopecia mit 17-beta-n-mono-substituierten-carbamoyl-4-aza-5-alpha-androst-1-en-3-onen.
JPH03501732A (ja) 1987-12-22 1991-04-18 ザ　リポソーム　カンパニー，インコーポレイテッド 多重ラメラリポソームの自発的小胞化方法
US5000887A (en) * 1988-05-17 1991-03-19 Liposome Technology, Inc. Preparation of uniform-size liposomes
EP0467954B1 (en) * 1989-03-31 1996-05-01 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
WO1992003123A1 (en) * 1990-08-28 1992-03-05 Liposome Technology, Inc. Liposome alternative bilayer formulations
US20040175417A1 (en) * 1990-10-19 2004-09-09 Gilead Sciences, Inc. Amphotericin B liposome preparation
GB9111611D0 (en) 1991-05-30 1991-07-24 Sandoz Ltd Liposomes
US6733776B1 (en) * 1992-04-02 2004-05-11 Anticancer, Inc. Method for promoting hair growth
US7556825B2 (en) * 1993-04-02 2009-07-07 Anticancer, Inc. Method for promoting hair growth
US7083572B2 (en) * 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
FI100692B (fi) * 1994-05-24 1998-02-13 Leiras Oy Menetelmä farmaseuttisten koostumusten valmistamiseksi, jolloin koostu mukset pohjautuvat mikroemulsiogeeleihin sekä uusia mikroemulsioihin p ohjautuvia geelejä
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
US6001812A (en) * 1995-04-28 1999-12-14 Societe L'oreal S.A. Modulating body/cranial hair growth with derivatives of the α-type melanocyte-stimulating hormone
JPH0971513A (ja) * 1995-09-07 1997-03-18 Taisho Pharmaceut Co Ltd 育毛剤
US5834014A (en) 1995-10-06 1998-11-10 The Regents Of The University Of Michigan Stimulation of hair follicles
JP3596835B2 (ja) * 1996-08-13 2004-12-02 株式会社ノエビア 養毛剤
US6030948A (en) * 1997-12-19 2000-02-29 Mann; Morris A. Hair regeneration compositions for treatment of alopecia and methods of application related thereto
US6265412B1 (en) 1998-05-26 2001-07-24 Taisho Pharmaceutical Co., Ltd. Minoxidil compositions for external use
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
JP4444385B2 (ja) * 1999-02-25 2010-03-31 帝人株式会社 リポソーム用時調製用キット
BR0010459A (pt) * 1999-03-11 2002-02-05 Fujisawa Pharmaceutical Co Preparação de lipossoma contendo derivado de ácido pipecólico e preparação sólida
CA2309373A1 (en) 1999-05-27 2000-11-27 Johnson & Johnson Consumer Companies, Inc. Novel topical formulations
US6596266B2 (en) * 2000-02-18 2003-07-22 Natural Science, Inc. Compositions containing minoxidil and saw palmetto for treating baldness
JP4780429B2 (ja) 2000-04-07 2011-09-28 大正製薬株式会社 ミノキシジル含有製剤
JP2004515453A (ja) 2000-05-05 2004-05-27 ウィスコンシン・アルムナイ・リサーチ・ファウンデーション 癌を化学療法および放射線療法に付する間に細胞を保護するための組成物および方法
IN188843B (enExample) * 2000-06-22 2002-11-09 Vinod Daftary Gautam Dr
WO2002007728A1 (en) 2000-07-19 2002-01-31 Knowles W Roy Hair loss prevention
DE10036799A1 (de) * 2000-07-28 2002-02-07 Beiersdorf Ag Neues Mittel zur Behandlung der Haare und der Kopfhaut
SE0100374D0 (sv) * 2001-02-07 2001-02-07 Pharmacia Ab Novel compositions of potassium channel openers and protein kinase c inhibitors and use thereof
ATE440593T1 (de) * 2001-03-27 2009-09-15 Phares Pharm Res Nv Verfahren und zusammensetzung zur solubilisierung einer biologisch wirksamen verbindung mit geringer wasserlíslichkeit
JP4796260B2 (ja) * 2001-04-05 2011-10-19 大正製薬株式会社 ミノキシジル含有製剤
WO2003013245A1 (en) 2001-08-07 2003-02-20 Wisconsin Alumni Research Foundation Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy
US6656460B2 (en) * 2001-11-01 2003-12-02 Yissum Research Development Method and composition for dry eye treatment
JP2006508912A (ja) * 2002-08-23 2006-03-16 メディゲーネ オンコロギー ゲゼルシャフト ミット ベシュレンクテル ハフツング 非小胞性カチオン脂質調製物
CA2500716A1 (en) * 2002-10-03 2004-04-15 University Of Mississippi Compositions comprising highly purified amphotericin b
EP1556392A1 (en) * 2002-10-16 2005-07-27 Neopharm, Inc. Cardiolipin molecules and method of synthesis
JP2004155690A (ja) * 2002-11-05 2004-06-03 Shiseido Co Ltd 養毛剤組成物
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
EP1643971A2 (en) * 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
KR100508019B1 (ko) * 2003-07-19 2005-08-17 한미약품 주식회사 고순도 1-안드로스텐 유도체의 제조 방법
ITMI20032019A1 (it) * 2003-10-17 2005-04-18 Fidia Farmaceutici Microemulsioni di retinoidi e composizioni farmaceutiche che le contengono
WO2005112957A1 (en) * 2004-05-21 2005-12-01 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
AU2005279934A1 (en) * 2004-08-30 2006-03-09 Theregen, Inc. Compositions and methods of promoting hair growth
MX2007003789A (es) 2004-10-04 2007-07-20 Qlt Usa Inc Suministro ocular de formulaciones polimericas para suministro.
EP1863518A2 (en) * 2005-03-30 2007-12-12 Wyeth Methods for stimulating hair growth by administering bmps
JP2006290841A (ja) * 2005-04-14 2006-10-26 Nippon Zettoc Co Ltd 化粧料の製造方法および化粧料
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
EP2029106A2 (en) 2006-06-07 2009-03-04 Foamix Ltd. Foamable vehicle comprising polypropylene glycol alkyl ether and pharmaceutical compositions thereof
HUE031951T2 (en) * 2006-10-10 2017-08-28 Jina Pharmaceuticals Inc Aqueous systems for lipid-based drug compounds; preparations, processes and their use
GB0623838D0 (en) * 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
CN101559038B (zh) 2009-05-21 2011-03-16 江苏黄河药业股份有限公司 非那雄胺的固体脂质纳米粒及其制备方法

Also Published As

Publication number Publication date
CA2737025A1 (en) 2010-04-01
MX2011003207A (es) 2011-11-04
WO2010036947A3 (en) 2010-06-10
HUE052571T2 (hu) 2021-05-28
EP2344198A4 (en) 2013-01-09
US9750812B2 (en) 2017-09-05
WO2010036947A2 (en) 2010-04-01
DK2344198T3 (da) 2020-11-30
US20110212167A1 (en) 2011-09-01
CY1123579T1 (el) 2022-03-24
EP2344198A2 (en) 2011-07-20
JP6196943B2 (ja) 2017-09-13
JP2017048188A (ja) 2017-03-09
JP2014221784A (ja) 2014-11-27
JP2012504135A (ja) 2012-02-16
EP2344198B1 (en) 2020-11-04
HRP20201860T1 (hr) 2021-04-16
LT2344198T (lt) 2021-02-25
ES2834006T3 (es) 2021-06-16
SI2344198T1 (sl) 2021-01-29
PT2344198T (pt) 2020-12-04
PL2344198T3 (pl) 2021-05-31

Similar Documents

Publication Publication Date Title
CA2737025C (en) Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof
JP3903061B2 (ja) 薬物を含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる非経口投与用製剤
AU2013371101B2 (en) Sustained-release lipid pre-concentrate of GnRH analogues and pharmaceutical composition comprising the same
CN104427977B (zh) 局部麻醉剂的储库制剂及其制备方法
EP3845247B1 (en) Use of amino acid based nutrients and pharmaceutical composition containing the same
JP2820688B2 (ja) 極性および中性脂質混合物を含有する胃腸管保護用組成物および胃腸管保護方法
JP2002533379A (ja) 生体内における局所的に非侵襲性である用途のための改善された製剤
US20110135714A1 (en) Compositions for external application, containing adenosyl cobalamin for improvement of skin diseases
JP2006524659A (ja) ケラチノサイトの過剰増殖、特に、アトピー性皮膚炎および乾癬を特徴とする疾患を治療するためのリルゾールの使用
CN109983013A (zh) 美洛昔康锌复合物微粒多囊脂质体制剂及其制备方法
JP2001502676A (ja) 障壁を通して活性成分を輸送するための調製物
CN102470104B (zh) 含有dha酯的非胃肠道给药的药用组合物
CH673395A5 (enExample)
CN1213964A (zh) 抗糖皮质激素药物
JP2937135B2 (ja) Ｐｇｅ１含有凍結乾燥製剤及び製法
WO2014090858A1 (en) Gel compositions
JP2514995B2 (ja) 経皮、経粘膜による物質の吸収を促進する組成物
WO2012122493A1 (en) Lipid based clopidogrel compositions, methods, and uses
CN121731308A (zh) 包含布瑞哌唑的药物组合物及其药物制剂、制备方法和应用
JPH04360832A (ja) リポソーム製剤
JPWO1998030221A1 (ja) 点眼用ジフルプレドナート含有ｏ／ｗエマルジョン組成物
CN1179721A (zh) 新型药物制剂

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240920

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240920

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240920

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250919

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250919